Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
---|
Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
---|
Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
---|
Across the recent three months, 4 analysts have shared their insights on Viridian Therapeutics (NASDAQ:VRDN), expressing a variety of opinions spanning from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
---|---|---|---|---|---|
Total Ratings | 3 | 1 | 0 | 0 | 0 |
Last 30D | 1 | 0 | 0 | 0 | 0 |
1M Ago | 2 | 1 | 0 | 0 | 0 |
2M Ago | 0 | 0 | 0 | 0 | 0 |
3M Ago | 0 | 0 | 0 | 0 | 0 |
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $34.25, a high estimate of $40.00, and a low estimate of $30.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 0.72%.
In examining recent analyst actions, we gain insights into how financial experts perceive Viridian Therapeutics. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
---|---|---|---|---|---|
Serge Belanger | Needham | Maintains | Buy | $30.00 | $30.00 |
Douglas Tsao | HC Wainwright & Co. | Maintains | Buy | $37.00 | - |
Laura Chico | Wedbush | Raises | Outperform | $40.00 | $39.00 |
Serge Belanger | Needham | Maintains | Buy | $30.00 | - |
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Viridian Therapeutics's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
Stay up to date on Viridian Therapeutics analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate VRDN-001 is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) being developed for the potential treatment for patients with thyroid eye disease.
Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.
Decline in Revenue: Over the 3 months period, Viridian Therapeutics faced challenges, resulting in a decline of approximately -31.43% in revenue growth as of 31 December, 2023. This signifies a reduction in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Viridian Therapeutics's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -92861.11%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Viridian Therapeutics's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -34.81%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Viridian Therapeutics's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -16.32%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Viridian Therapeutics's debt-to-equity ratio is below the industry average. With a ratio of 0.09, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: VRDN